These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15826590)

  • 41. A survey of palivizumab for infants with cystic fibrosis in the UK.
    McCormick J; Southern KW
    Arch Dis Child; 2007 Jan; 92(1):87-8. PubMed ID: 17185451
    [No Abstract]   [Full Text] [Related]  

  • 42. Bronchiolitis.
    Smyth RL; Openshaw PJ
    Lancet; 2006 Jul; 368(9532):312-22. PubMed ID: 16860701
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Managing bronchiolitis and respiratory syncytial virus: finding the yellow brick road.
    Hall CB
    Arch Pediatr Adolesc Med; 2004 Feb; 158(2):111-2. PubMed ID: 14757601
    [No Abstract]   [Full Text] [Related]  

  • 44. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hospitalization for acute bronchiolitis, gestational age, and palivizumab].
    Lapeña López de Armentia S; Castañón López L; Martínez Badás JP; Alvaro Iglesias E
    An Esp Pediatr; 2001 Oct; 55(4):378-9. PubMed ID: 11578549
    [No Abstract]   [Full Text] [Related]  

  • 46. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina.
    Fariña D; Rodríguez SP; Bauer G; Novali L; Bouzas L; González H; Gilli C; Laffaire E
    Pediatr Infect Dis J; 2002 Apr; 21(4):287-91. PubMed ID: 12075758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience.
    Drummond D; Thumerelle C; Reix P; Fayon M; Epaud R; Clement A; Mahloul M; Habouria D; Delacourt C; Hadchouel A
    Pediatr Pulmonol; 2016 Jul; 51(7):688-95. PubMed ID: 26636747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.
    Meissner HC; Rennels MB; Pickering LK; Hall CB
    Pediatr Infect Dis J; 2004 Mar; 23(3):284-5. PubMed ID: 15014320
    [No Abstract]   [Full Text] [Related]  

  • 49. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group.
    Groothuis JR
    Pediatr Infect Dis J; 2001 Jun; 20(6):628-30. PubMed ID: 11419509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respiratory syncytial virus: different criteria for palivizumab use in different areas?
    Mitchell I
    South Med J; 2007 Jul; 100(7):661-2. PubMed ID: 17639741
    [No Abstract]   [Full Text] [Related]  

  • 52. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Onuzo OC
    Cardiol Young; 2004 Aug; 14(4):466-7; author reply 467-9. PubMed ID: 15680062
    [No Abstract]   [Full Text] [Related]  

  • 53. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of bronchiolitis in infants and children.
    Viswanathan M; King VJ; Bordley C; Honeycutt AA; Wittenborn J; Jackman AM; Sutton SF; Lohr KN
    Evid Rep Technol Assess (Summ); 2003 Jan; (69):1-5. PubMed ID: 12624885
    [No Abstract]   [Full Text] [Related]  

  • 55. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants.
    Farber HJ; Buckwold FJ; Lachman B; Simpson JS; Buck E; Arun M; Valadez AM; Ruiz T; Alonzo J; Henry A; Cos-Okpalla N; Nguyen K; Brendel W; Small J; Glomb WB
    Pediatrics; 2016 Aug; 138(2):. PubMed ID: 27432850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Respiratory syncytial virus: concerns and control.
    McCarthy CA; Hall CB
    Pediatr Rev; 2003 Sep; 24(9):301-9. PubMed ID: 12949266
    [No Abstract]   [Full Text] [Related]  

  • 58. Studies recommending palivizumab restriction have serious deficiencies.
    Stewart DL
    J Manag Care Pharm; 2010 Sep; 16(7):509-11; author reply 511-2, discussion 512-4. PubMed ID: 20726681
    [No Abstract]   [Full Text] [Related]  

  • 59. Palivizumab (synagis): counting "costs" and values.
    Carter BS
    Pediatrics; 2000 Nov; 106(5):1168-9. PubMed ID: 11185071
    [No Abstract]   [Full Text] [Related]  

  • 60. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.